Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigation of Long Non-Coding RNAs <i>H19</i> rs3741219, <i>MEG3</i> rs7158663, <i>POLR2E</i> rs3787016, and <i>ANRIL</i> rs10757274 with Breast Cancer Susceptibility and Clinicopathological Characteristics in a Mexican Population.

Non-coding RNA·2026
Same author

Real-World Outcomes and Clinicopathologic Features of Human Epidermal Growth Factor Receptor 2-Low Breast Cancer in a Mexican Cohort.

JCO global oncology·2026
Same author

Factors influencing care for patients with gynecologic malignancies from culturally and linguistically diverse backgrounds: a questionnaire study (iCALD-2).

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Multidisciplinary Management of Paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis Associated With Ovarian Teratoma: A Case Report.

Cureus·2026
Same author

Orbital Exenteration for Primary Tumors or Secondary to Extension Among Hospital Patients: A Retrospective Case Study.

Journal of maxillofacial and oral surgery·2026
Same author

[Sensitivity and validity of sentinel node biopsy in early-stage cervical cancer at an oncology institution].

Cirugia y cirujanos·2026

Related Experiment Video

Updated: Jun 20, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.6K

Second Mexican Consensus on Endometrial Cancer.

David F Cantú-de León1, Flavia Morales-Vásquez2,3, Claudia Cano-Blanco2

  • 1Gineco-Oncología, Instituto Nacional de Cancerología, Tlalpan, Ciudad de México.

Cirugia Y Cirujanos
|October 20, 2025
PubMed
Summary
This summary is machine-generated.

This study developed 33 evidence-based recommendations for diagnosing and managing endometrial cancer in Mexico. These guidelines aim to improve care quality for this significant public health issue.

Keywords:
Clinical practice guidelinesCáncer de endometrioEndometrial cancerEvidence-based medicineFemale neoplasmsGuías de práctica clínicaMedicina basada en evidenciaNeoplasias de la mujer

More Related Videos

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

10.8K
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

13.0K

Related Experiment Videos

Last Updated: Jun 20, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.6K
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

10.8K
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

13.0K

Area of Science:

  • Gynecologic Oncology
  • Public Health

Background:

  • Endometrial cancer is a leading cause of cancer incidence and mortality globally.
  • In Mexico, it is the second most common gynecologic cancer, posing a significant public health challenge.

Purpose of the Study:

  • To establish interinstitutional recommendations for endometrial cancer diagnosis and management within the Mexican health system.
  • To enhance the quality of care for patients diagnosed with endometrial cancer in Mexico.

Main Methods:

  • A modified Delphi panel approach was employed, involving expert oncologists.
  • In-person voting with an 80% agreement threshold was used to finalize recommendations.

Main Results:

  • Formal consensus was achieved on 33 clinical recommendations.
  • Recommendations were based on expert evaluation of identified evidence.

Conclusions:

  • The guideline offers crucial clinical recommendations for endometrial cancer.
  • Implementation aims to improve patient care quality in Mexico.